Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma

Shanghai Jiao Tong University

Status and phase

Completed

Phase 4

Conditions

Glaucoma, Neovascular

Diabetic Retinopathy

Treatments

Drug: ranibizumab

Study type

Interventional

Funder types

Other

Identifiers

NCT02647515

XShen

Details and patient eligibility

About

To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of postvitrectomy diabetic vitreous hemorrhage (PDVH) accompanied by neovascular glaucoma (NVG) as a means of preventing recurrent vitreous hemorrhage （VH） and optimizing postoperative intraocular pressure（IOP）control.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

age≥18 years
PDVH obscuring the disc and vessels for more than 14 days and no evidence of retinal detachment after primary vitrectomy for PDR-related complications such as nonclearing VH, macula-involving or macula-threatening tractional retinal detachment, or fibrovascular proliferation with vitreoretinal adhesions
NVG occurred following PDVH less than 4 weeks (NVG was diagnosed when an IOP elevation of 22mmHg or more was accompanied by neovascularization of the iris and/or the anterior chamber angle)

Exclusion criteria

intraoperative use of long-acting gas or silicone oil in primary vitrectomy, repeat vitrectomy after primary vitrectomy for retinal diseases other than VH, previous history of vitrectomy
previous intravitreal injection of ranibizumab or bevacizumab in either eye
previous intravitreal corticosteroids injection in either eye
pregnancy or current oral contraceptive intake
usage of clopidogrel bisulfate or coumadin
uncontrolled hypertension and cardiac disease
uncontrolled renal or liver disease